Tsuyoshi Yamato

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.

H. Makita, W. Busse, E. Bleecker, 2019, The Lancet. Respiratory medicine.